Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study

Pediatric Hematology and Oncology
Ellen RuudFinn Wesenberg

Abstract

Asparaginase is essential in the treatment of lymphoproliferative malignancies, but it is associated with several side effects. The objective of this study was to compare asparaginase-induced alterations of the coagulation inhibitors and the impact on central line-associated thrombosis in children treated according to 2 different asparaginase regimens. The study enrolled 30 children treated for acute lymphoblastic leukemia, and they were divided into 2 groups with respect to asparaginase preparation and protocol (NOPHO ALL-1992 versus NOPHO ALL-2000). The coagulation inhibitors antithrombin, protein C, and proteins S were measured prior to and during asparaginase therapy, and incidence of central line-associated thromboses was compared to evaluate the protocols' thrombogenicity. Thirteen children received Erwinia asparaginase and 17 children received E. coli asparaginase. Independent of protocol, the coagulation inhibitors were significantly reduced during asparaginase therapy (p < .001), and central line-associated thromboses were frequent. Four children developed thrombosis in the course of asparaginase therapy, and there was a correlation between asparaginase-induced fall of antithrombin and occurrence of new thromboses (p =...Continue Reading

References

Jan 1, 1994·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·M AndrewL Mitchell
Jan 1, 1995·International Journal of Clinical & Laboratory Research·U Nowak-GöttlH Jürgens
Aug 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BoosH Jürgens
Oct 13, 1998·Critical Reviews in Oncology/hematology·H J Müller, J Boos
Oct 27, 2001·British Journal of Clinical Pharmacology·B K AlbertsenK Schmiegelow
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melina Verso, Giancarlo Agnelli
Dec 20, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GattaUNKNOWN EUROCARE Working Group
Apr 3, 2004·British Journal of Haematology·João Paulo Vieira Pinheiro, Joachim Boos

❮ Previous
Next ❯

Citations

Jan 1, 2009·International Journal of General Medicine·Yan LiuNing Xu
Mar 17, 2009·Best Practice & Research. Clinical Haematology·Ulrike Nowak-GöttlLesley G Mitchell
Apr 29, 2009·Acta Paediatrica·Sólveig HafsteinsdóttirAsgeir Haraldsson
Jan 16, 2008·Journal of Thrombosis and Haemostasis : JTH·S KuhleL G Mitchell
Sep 13, 2013·The Cochrane Database of Systematic Reviews·Reineke A SchootCornelia H van Ommen
Aug 26, 2006·The Journal of Biological Chemistry·Rachel B ReinertTracy G Anthony
Sep 3, 2021·Seminars in Thrombosis and Hemostasis·Rasmus Søgaard HansenAnne-Mette Hvas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.